Eton Pharmaceuticals, Inc. Operating Expenses
Eton Pharmaceuticals, Inc. (ETON) reported Operating Expenses of $12.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-06-30 was $12.62M, a 5.82% decline year-over-year.
- Eton Pharmaceuticals, Inc. operating expenses for the quarter ending 2026-03-31 was $12.32M, a 19.26% increase year-over-year.
- Eton Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-12-31 was $10.64M, a 81.91% increase year-over-year.
- Eton Pharmaceuticals, Inc. operating expenses for the quarter ending 2025-09-30 was $9.22M, a 59.12% increase year-over-year.
- Eton Pharmaceuticals, Inc. operating expenses for fiscal 2025 was $43.58M, a 67.58% increase from fiscal 2024.
- Eton Pharmaceuticals, Inc. operating expenses for fiscal 2024 was $26.01M, a 16.87% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. operating expenses for fiscal 2023 was $22.25M, a 1.44% decline from fiscal 2022.
- Eton Pharmaceuticals, Inc. operating expenses for fiscal 2022 was $22.58M, a 10.14% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 5 month | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 8 month | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $12.62M 10-Q · filed 2026-08-13 | $24.94M 10-Q · filed 2026-08-13 | $35.58M derived: sum of 3 quarters · filed 2026-08-13 | $44.79M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2026-03-31 | $12.32M 10-Q · filed 2026-05-14 | $22.96M derived: sum of 2 quarters · filed 2026-05-14 | $32.17M derived: sum of 3 quarters · filed 2026-05-14 | $45.57M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-12-31 | $10.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $19.85M derived: sum of 2 quarters · filed 2026-03-19 | $33.25M derived: sum of 3 quarters · filed 2026-08-13 | $43.58M 10-K · filed 2026-03-19 | ||||||
| 2025-09-30 | $9.22M 10-Q · filed 2025-11-06 | $22.62M derived: sum of 2 quarters · filed 2026-08-13 | $32.95M 10-Q · filed 2025-11-06 | $38.80M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-06-30 | $13.40M 10-Q · filed 2026-08-13 | $23.73M 10-Q · filed 2026-08-13 | $29.58M derived: sum of 3 quarters · filed 2026-08-13 | $35.37M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-03-31 | $10.33M 10-Q · filed 2026-05-14 | $16.18M derived: sum of 2 quarters · filed 2026-05-14 | $21.97M derived: sum of 3 quarters · filed 2026-05-14 | $30.53M derived: sum of 4 quarters · filed 2026-05-14 | ||||||
| 2024-12-31 | $5.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $11.64M derived: sum of 2 quarters · filed 2026-03-19 | $20.20M derived: sum of 3 quarters · filed 2026-03-19 | $26.01M 10-K · filed 2026-03-19 | ||||||
| 2024-09-30 | $5.79M 10-Q · filed 2025-11-06 | $14.35M derived: sum of 2 quarters · filed 2025-11-06 | $20.16M 10-Q · filed 2025-11-06 | $25.78M derived: sum of 4 quarters · filed 2026-03-19 | ||||||
| 2024-06-30 | $8.56M 10-Q · filed 2025-08-07 | $14.37M 10-Q · filed 2025-08-07 | $19.99M derived: sum of 3 quarters · filed 2026-03-19 | $24.94M derived: sum of 4 quarters · filed 2026-03-19 | ||||||
| 2024-03-31 | $5.81M 10-Q · filed 2025-05-13 | $11.43M derived: sum of 2 quarters · filed 2026-03-19 | $16.38M derived: sum of 3 quarters · filed 2026-03-19 | $22.18M derived: sum of 4 quarters · filed 2026-03-19 | ||||||
| 2023-12-31 | $5.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $10.57M derived: sum of 2 quarters · filed 2026-03-19 | $16.37M derived: sum of 3 quarters · filed 2026-03-19 | $22.25M 10-K · filed 2026-03-19 | ||||||
| 2023-09-30 | $4.95M 10-Q · filed 2024-11-12 | $10.75M derived: sum of 2 quarters · filed 2024-11-12 | $16.63M 10-Q · filed 2024-11-12 | $21.93M derived: sum of 4 quarters · filed 2025-03-18 | ||||||
| 2023-06-30 | $5.80M 10-Q · filed 2024-08-08 | $11.68M 10-Q · filed 2024-08-08 | $16.98M derived: sum of 3 quarters · filed 2025-03-18 | $21.89M derived: sum of 4 quarters · filed 2025-03-18 | ||||||
| 2023-03-31 | $5.88M 10-Q · filed 2024-05-09 | $11.18M derived: sum of 2 quarters · filed 2025-03-18 | $16.09M derived: sum of 3 quarters · filed 2025-03-18 | $22.04M derived: sum of 4 quarters · filed 2025-03-18 | ||||||
| 2022-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $10.21M derived: sum of 2 quarters · filed 2025-03-18 | $16.16M derived: sum of 3 quarters · filed 2025-03-18 | $22.58M 10-K · filed 2025-03-18 | ||||||
| 2022-09-30 | $4.91M 10-Q · filed 2023-11-09 | $10.87M derived: sum of 2 quarters · filed 2023-11-09 | $17.28M 10-Q · filed 2023-11-09 | $21.69M derived: sum of 4 quarters · filed 2024-03-14 | ||||||
| 2022-06-30 | $5.95M 10-Q · filed 2023-08-10 | $12.37M 10-Q · filed 2023-08-10 | $16.77M derived: sum of 3 quarters · filed 2024-03-14 | $22.74M derived: sum of 4 quarters · filed 2024-03-14 | ||||||
| 2022-03-31 | $6.41M 10-Q · filed 2023-05-11 | $6.54M 10-Q · filed 2022-05-12 | $10.82M derived: sum of 2 quarters · filed 2024-03-14 | $16.79M derived: sum of 3 quarters · filed 2024-03-14 | $22.01M derived: sum of 4 quarters · filed 2024-03-14 | |||||
| 2021-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $10.38M derived: sum of 2 quarters · filed 2024-03-14 | $15.59M derived: sum of 3 quarters · filed 2024-03-14 | $20.50M 10-K · filed 2024-03-14 | $20.70M 10-K · filed 2022-03-16 | |||||
| 2021-09-30 | $5.97M 10-Q · filed 2022-11-10 | $6.00M 10-Q · filed 2021-11-16 | $11.19M derived: sum of 2 quarters · filed 2022-11-10 | $16.09M 10-Q · filed 2022-11-10 | $16.20M 10-Q · filed 2021-11-16 | $23.18M derived: sum of 4 quarters · filed 2023-03-16 | ||||
| 2021-06-30 | $5.22M 10-Q · filed 2022-08-11 | $5.26M 10-Q · filed 2021-08-16 | $10.13M 10-Q · filed 2022-08-11 | $10.20M 10-Q · filed 2021-08-16 | $17.21M derived: sum of 3 quarters · filed 2023-03-16 | $23.47M derived: sum of 4 quarters · filed 2023-03-16 | ||||
| 2021-03-31 | $4.94M 10-Q · filed 2022-05-12 | $11.99M derived: sum of 2 quarters · filed 2023-03-16 | $18.25M derived: sum of 3 quarters · filed 2023-03-16 | $22.78M derived: sum of 4 quarters · filed 2023-03-16 | ||||||
| 2020-12-31 | $7.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $13.31M derived: sum of 2 quarters · filed 2023-03-16 | $17.84M derived: sum of 3 quarters · filed 2023-03-16 | $26.71M 10-K · filed 2023-03-16 | $26.86M 10-K · filed 2021-03-16 | |||||
| 2020-09-30 | $6.25M 10-Q · filed 2021-11-16 | $10.79M derived: sum of 2 quarters · filed 2021-11-16 | $19.66M 10-Q · filed 2021-11-16 | $22.32M derived: sum of 4 quarters · filed 2021-11-16 | ||||||
| 2020-06-30 | $4.53M 10-Q · filed 2021-08-16 | $13.41M 10-Q · filed 2021-08-16 | $16.07M derived: sum of 3 quarters · filed 2021-08-16 | $21.11M derived: sum of 4 quarters · filed 2021-08-16 | ||||||
| 2020-03-31 | $8.88M 10-Q · filed 2021-05-13 | $11.54M derived: sum of 2 quarters · filed 2021-05-13 | $16.58M derived: sum of 3 quarters · filed 2021-05-13 | $19.93M derived: sum of 4 quarters · filed 2021-05-13 | ||||||
| 2019-12-31 | $2.66M 10-K · filed 2020-03-05 | $7.70M derived: sum of 2 quarters · filed 2020-11-12 | $11.05M derived: sum of 3 quarters · filed 2020-11-12 | $19.11M 10-K · filed 2022-03-16 | ||||||
| 2019-09-30 | $5.04M 10-Q · filed 2020-11-12 | $8.39M derived: sum of 2 quarters · filed 2020-11-12 | $16.45M 10-Q · filed 2020-11-12 | $18.73M derived: sum of 4 quarters · filed 2020-11-12 | ||||||
| 2019-06-30 | $3.35M 10-Q · filed 2020-08-12 | $11.40M 10-Q · filed 2020-08-12 | $13.69M derived: sum of 3 quarters · filed 2020-08-12 | $16.06M derived: sum of 4 quarters · filed 2020-08-12 | ||||||
| 2019-03-31 | $8.05M 10-Q · filed 2020-05-14 | $10.34M derived: sum of 2 quarters · filed 2020-05-14 | $12.71M derived: sum of 3 quarters · filed 2020-05-14 | $15.41M derived: sum of 4 quarters · filed 2020-05-14 | ||||||
| 2018-12-31 | $2.29M 10-K · filed 2020-03-05 | $4.66M derived: sum of 2 quarters · filed 2020-03-05 | $7.36M derived: sum of 3 quarters · filed 2020-03-05 | $10.32M 10-K · filed 2021-03-16 | ||||||
| 2018-09-30 | $2.37M 10-K · filed 2020-03-05 | $5.07M derived: sum of 2 quarters · filed 2020-03-05 | $8.04M 10-Q · filed 2019-11-14 | |||||||
| 2018-06-30 | $2.70M 10-K · filed 2020-03-05 | $5.66M 10-Q · filed 2019-08-06 | ||||||||
| 2018-03-31 | $2.96M 10-K · filed 2020-03-05 | |||||||||
| 2017-12-31 | $7.15M 10-K · filed 2020-03-05 | |||||||||
| 2017-09-30 | $2.77M 10-Q · filed 2018-12-20 | $4.95M 10-Q · filed 2018-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |